SMARCB1 and cancer: Exploiting synthetic lethal interactions caused by specific mutations offers more promise, as in SMARCA4‐mutant cancers reliant on SMARCA2 or SMARCB1‐mutant tumors vulnerable to ncBAF‐targeting.